Corson Technology announced that it recently received a letter from the Shanghai Stock Exchange to supervise the sale of shares in the wholly-owned subsidiary Corson Healthcare. In the first three quarters of 2024 and 2025, Keson Medical achieved revenue of 366 million yuan and 354 million yuan, net profit of 41.1218 million yuan, and 47.2414 million yuan, respectively, while the company continued to lose money during the same period. The exchange requires the company to further disclose a number of details, including the reason for the loss, the financial impact of the transaction, etc. After interviewing relevant personnel and reviewing data, the independent directors found no relationship or undisclosed interest arrangements in the transaction. Regarding internal transactions, after a special audit, the transaction between 2018 and September 30, 2025, Coson Medical's transactions with the company and subsidiaries was necessary, reasonably priced, and of commercial substance.

Corson Technology announced that it recently received a letter from the Shanghai Stock Exchange to supervise the sale of shares in the wholly-owned subsidiary Corson Healthcare. In the first three quarters of 2024 and 2025, Keson Medical achieved revenue of 366 million yuan and 354 million yuan, net profit of 41.1218 million yuan, and 47.2414 million yuan, respectively, while the company continued to lose money during the same period. The exchange requires the company to further disclose a number of details, including the reason for the loss, the financial impact of the transaction, etc. After interviewing relevant personnel and reviewing data, the independent directors found no relationship or undisclosed interest arrangements in the transaction. Regarding internal transactions, after a special audit, the transaction between 2018 and September 30, 2025, Coson Medical's transactions with the company and subsidiaries was necessary, reasonably priced, and of commercial substance.